Ana Gupte, a Leerink analyst, says rhetoric from New York regulators won’t derail a $69 billion CVS-Aetna deal.
According to a Fierce Healthcare report, New York’s approval is the final big obstacle standing in the way of the merger. New York State Superintendent of Financial Services Maria Vulla questioned the implications of the deal.
“Large corporate for-profit conglomerates do not have a good history of serving the public above their shareholders,” Vulla said in a statement. “And, here, we have independent pharmacists, medical providers, the uninsured, consumers suffering from too high pharmaceutical costs, who may suffer from this transaction.”
To read the full report on Fierce Healthcare, click here.